Cdkl在浆液性卵巢癌中的表达及其与化疗耐药及预后的相关性

目的：卵巢癌是女性生殖致死率最高的恶性肿瘤。Cdkl作为细胞周期依赖性激酶中的核心分子，对肿瘤细胞的发生发展具有重要作用。本文旨在探讨Cdkl蛋白在上皮性浆液性卵巢癌中的表达情况，并分析其表达水平与患者临床病理特征、化疗反应及预后之间的关系。方法：采用免疫组化法检测68例浆液性卵巢癌中Cdkl蛋白的表达情况，并结合临床资料分析Cdkl蛋白的表达水平在浆液性卵巢癌患者中的意义。结果：Cdkl在浆液性卵巢癌患者中具有不同程度的阳性表达，其表达水平和患者的年龄、病理分化程度、淋巴结转移情况及临床分期无明显相关性（P〉0．05），但是其高表达与化疗耐药明显相关（P=0．040）。化疗耐药的卵巢癌患者中Cdkl的蛋白表达明显高于化疗敏感组，并且生存分析发现，高表达Cdkl的患者预后较差。结论：本研究证明Cdkl在浆液性卵巢癌中有较高表达，并且Cdkl的表达与卵巢癌化疗后复发有关，高的Cdkl表达预示着较差的预后。Cdkl可能是晚期浆液性卵巢癌治疗的新靶点。

Expression of Cdkl Protein in Serous Ovarian Cancer Correlates to Chemo-Resistance and Prognosis of Patients

Objective： To study the Cdkl protein expression of ovarian cancer tissues and the relationship between Cdkl level and the chemotherapy resistance and prognosis of ovarian cancer patients. Methods： The Cdkl protein expression was assessed by immunehistochemistry （1HC） in 68 specimens of serous ovarian cancer. A correlation was analyzed between Cdkt protein expression and clinical pathological features. The Kaplan-meier curve was used to analyse the correlation of Cdkl expression with prognosis of ovarian cancer patients. Results Cdkl protein expression level was not related to age, lymph nodes metastasis, clinical stage and pathological differentiation（P 〉 0.05 ）, while high Cdk 1 expression was associated with chemotherapy resistance（P = 0.040）. And the chemo-resistance patients group had a much higher Cdkl expression. Survival analysis found out that Cdkl expression was an independent factor of PFS of ovarian cancer patients. Conclusion： Our data represent firstly that Cdkl protein expression may contribute to chemotherapy resistance and prognosis of serous ovarian carcinoma. Cdkl may be a promising therapy target for serous ovarian cancer.